LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

Search

Twist Bioscience Corp

Fechado

SetorSaúde

49.55 2.61

Visão Geral

Variação de preço das ações

24h

Atual

Mín

48.29

Máximo

50.63

Indicadores-chave

By Trading Economics

Rendimento

-3.4M

-31M

Vendas

4.7M

104M

Margem de lucro

-29.419

Funcionários

979

EBITDA

-3.2M

-24M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+7.13% upside

Dividendos

By Dow Jones

Próximos Ganhos

4 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

347M

2.9B

Abertura anterior

46.94

Fecho anterior

49.55

Sentimento de Notícias

By Acuity

50%

50%

167 / 351 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Twist Bioscience Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

25 de fev. de 2026, 23:25 UTC

Ações em Alta

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25 de fev. de 2026, 23:15 UTC

Ganhos

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25 de fev. de 2026, 23:54 UTC

Conversa de Mercado

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25 de fev. de 2026, 23:47 UTC

Ganhos

Ferrovial 4Q Net EUR197M >FER.MC

25 de fev. de 2026, 23:45 UTC

Ganhos

Ferrovial 4Q Rev EUR2.72B >FER.MC

25 de fev. de 2026, 23:42 UTC

Ganhos

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25 de fev. de 2026, 23:38 UTC

Conversa de Mercado

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com: Company's Business Operations Remain Normal >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com FY EPS CNY47.67 >TCOM

25 de fev. de 2026, 23:06 UTC

Ganhos

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25 de fev. de 2026, 23:01 UTC

Ganhos

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25 de fev. de 2026, 23:00 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

25 de fev. de 2026, 23:00 UTC

Conversa de Mercado
Ganhos

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25 de fev. de 2026, 22:56 UTC

Conversa de Mercado
Ganhos

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25 de fev. de 2026, 22:43 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25 de fev. de 2026, 22:40 UTC

Conversa de Mercado
Ganhos

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25 de fev. de 2026, 22:40 UTC

Ganhos

Karoon Energy Says Search for New CFO Well Advanced

25 de fev. de 2026, 22:39 UTC

Ganhos

Karoon Energy Says CFO Ray Church to Leave Company

25 de fev. de 2026, 22:39 UTC

Ganhos

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25 de fev. de 2026, 22:38 UTC

Ganhos

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Comparação entre Pares

Variação de preço

Twist Bioscience Corp Previsão

Preço-alvo

By TipRanks

7.13% parte superior

Previsão para 12 meses

Média 52 USD  7.13%

Máximo 58 USD

Mínimo 50 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Twist Bioscience Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

6

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

31.56 / 38.6884Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

167 / 351 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat